百克生物(688276.SH)業績快報:2022年度淨利潤1.82億元、同比下降25.42%
格隆匯2月24日丨百克生物(688276.SH)發佈2022年度業績快報,實現營業總收入10.71億元,同比下降10.86%;歸屬於母公司所有者的淨利潤1.82億元,同比下降25.42%;歸屬於母公司所有者的扣除非經常性損益的淨利潤1.67億元,同比下降28.58%;基本每股收益0.44元。
報吿期內,影響公司經營業績的主要因素包括:1、2022年度,受新冠疫情影響,人員流動性減少,終端疫苗接種存在一定困難,尤其是流感疫苗接種季未能有效銷售及接種,造成報吿期內營業總收入一定程度下滑。
2、公司按照《企業會計準則》以及公司會計政策、會計估計的相關規定,基於謹慎性原則,對截至2022年12月31日公司及下屬子公司的存貨等資產進行了減值測試,對預計無法實現銷售的庫存商品鼻噴流感減毒活疫苗計提存貨跌價準備;同時對因近效期等原因導致的無法使用的鼻噴給藥裝置等原材料及毀損的產成品做報廢處置。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.